HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Soluble epoxide hydrolase is involved in the development of atherosclerosis and arterial neointima formation by regulating smooth muscle cell migration.

Abstract
Epoxyeicosatrienoic acids (EETs) have beneficial effects on cardiovascular disease. Soluble epoxide hydrolase (sEH) metabolizes EETs to less active diols, thus diminishing their biological activity. sEH inhibitors can suppress the progression of atherosclerotic lesions in animal models. However, the regulation of sEH in vascular smooth muscle cells (VSMCs) and role of sEH in patients with atherosclerosis have not been evaluated. We hypothesize that sEH in VSMCs plays a pivotal role in atherosclerosis and injury-induced neointima formation. In this study, sEH expression in human autopsy atherosclerotic plaque was determined by immunohistochemistry. In cultured rat and human VSMCs, the phenotypic switching marker and sEH expression induced by platelet-derived growth factor-BB (PDGF-BB) were examined by Western blot analysis. Carotid-artery balloon injury was performed after adenovirus-mediated overexpression of sEH or oral administration of a potent sEH inhibitor in Sprague-Dawley rats. sEH was highly expressed in VSMCs of the intima and media within human atherosclerotic plaque. In vitro, PDGF-BB upregulated the expression in VSMCs after transcription and promoted cell proliferation and migration; the latter effect could be largely attenuated by an sEH inhibitor. Adenovirus-mediated overexpression of sEH could mimic the effect of PDGF-BB and induce VSMC proliferation and migration. In vivo, the sEH inhibitor led to a significant decrease in injury-induced neointima formation in a rat carotid-artery injury model. These data establish the effect of sEH expression on atherosclerotic progression and vascular remodeling after injury, thus identifying a novel integrative role for sEH in VSMC phenotypic modulation and migration. Blocking sEH activity may be a potential therapeutic approach for ameliorating vascular occlusive disease.
AuthorsQingjie Wang, Leijun Huo, Jinlong He, Wenshuang Ding, Hang Su, Dongping Tian, Carrie Welch, Bruce D Hammock, Ding Ai, Yi Zhu
JournalAmerican journal of physiology. Heart and circulatory physiology (Am J Physiol Heart Circ Physiol) Vol. 309 Issue 11 Pg. H1894-903 (Dec 01 2015) ISSN: 1522-1539 [Electronic] United States
PMID26453326 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 the American Physiological Society.
Chemical References
  • 1-(1-methanesulfonylpiperidin-4-yl)-3-(4-trifluoromethoxyphenyl)urea
  • Eicosanoids
  • Enzyme Inhibitors
  • Phenylurea Compounds
  • Piperidines
  • Proto-Oncogene Proteins c-sis
  • Becaplermin
  • Epoxide Hydrolases
  • EPHX2 protein, human
  • Ephx2 protein, mouse
Topics
  • Adolescent
  • Adult
  • Aged
  • Animals
  • Atherosclerosis (enzymology, genetics, pathology, prevention & control)
  • Becaplermin
  • Carotid Artery Injuries (enzymology, genetics, pathology, therapy)
  • Cell Dedifferentiation
  • Cell Movement (drug effects)
  • Cell Proliferation
  • Cells, Cultured
  • Coronary Artery Disease (enzymology, genetics, pathology)
  • Disease Models, Animal
  • Disease Progression
  • Eicosanoids (metabolism)
  • Enzyme Inhibitors (pharmacology)
  • Epoxide Hydrolases (antagonists & inhibitors, genetics, metabolism)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Muscle, Smooth, Vascular (drug effects, enzymology, pathology)
  • Myocytes, Smooth Muscle (drug effects, enzymology, pathology)
  • Neointima
  • Phenotype
  • Phenylurea Compounds (pharmacology)
  • Piperidines (pharmacology)
  • Proto-Oncogene Proteins c-sis (pharmacology)
  • Rats, Sprague-Dawley
  • Signal Transduction
  • Time Factors
  • Transfection
  • Vascular Remodeling
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: